ProPhase Labs (PRPH) Misses Q3 EPS by 33c; Reports Cash and Cash Equivalents of $22.9M

ProPhase Labs (NASDAQ: PRPH) reported Q3 EPS of ($0.26), $0.33 worse than the analyst estimate of $0.07. Revenue for the quarter came in at $9.5 million versus the consensus estimate of $9.08 million.

For earnings history and earnings-related data on ProPhase Labs (PRPH) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Wolfe Research upgrades Biogen, AbbVie on pipeline strength and valuation
• Ideal Power (IPWR) Tops Q2 EPS by 2c